P2Y12 Inhibitor Monotherapy Beneficial for Patients Who Undergo PCI
FRIDAY, June 6, 2025 -- For patients who undergo percutaneous coronary intervention (PCI) and discontinue dual antiplatelet therapy (DAPT), P2Y12 inhibitor monotherapy is associated with a lower risk for major adverse cardiac and cerebrovascular...
FRIDAY, June 6, 2025 -- For patients who undergo percutaneous coronary intervention (PCI) and discontinue dual antiplatelet therapy (DAPT), P2Y12 inhibitor monotherapy is associated with a lower risk for major adverse cardiac and cerebrovascular...
